RCKT - רווח נקי למניה ב-12 החודשים האחרונים Rocket Pharma

Demand for gene therapy for pathologies is independent of GDP, rendering the sector non-cyclical. On GURU.Markets, this linear chart of TTM earnings per share demonstrates a sideways trend, where -0.18 indicates the current level. The Rocket Pharmaceuticals (RCKT) strategy is based on strict ESG bioethics, yet a narrow focus on rare diseases creates high binary risks due to the absence of commercial products.

Fundamental asset selection requires an analysis of real earnings per share, which allows for an assessment of business efficiency regardless of the total issuance volume. This metric measures annual net profit, reflecting the ability of Rocket Pharmaceuticals (RCKT) to monetize its exclusive developments in the field of gene therapy for rare diseases, as clearly demonstrated by the 12-month net income per share chart.